Holen Sie sich die Stockscreener-App
294.64
1.65%
-4.93
Handel nachbörslich:
293.00
-1.64
-0.56%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MDGL?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$299.57
Offen:
$300.11
24-Stunden-Volumen:
305.94K
Relative Volume:
0.86
Marktkapitalisierung:
$7.00B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-518.67M
KGV:
-11.73
EPS:
-25.12
Netto-Cashflow:
$-438.32M
1W Leistung:
-6.61%
1M Leistung:
-6.15%
6M Leistung:
-15.99%
1J Leistung:
+42.39%
1-Tages-Spanne:
$291.16
$307.49
1-Wochen-Bereich:
$287.46
$318.27
52-Wochen-Spanne:
$200.63
$377.46
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Firmenname
Madrigal Pharmaceuticals Inc
Sektor
Branche
Telefon
404-380-9263
Adresse
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Vergleichen Sie MDGL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
294.64 | 7.00B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-28 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | Bestätigt | H.C. Wainwright | Buy |
| 2024-06-28 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2024-04-22 | Eingeleitet | BofA Securities | Underperform |
| 2024-03-15 | Hochstufung | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | Eingeleitet | Citigroup | Buy |
| 2024-02-26 | Herabstufung | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | Bestätigt | Oppenheimer | Outperform |
| 2022-12-19 | Bestätigt | H.C. Wainwright | Buy |
| 2022-12-19 | Bestätigt | Piper Sandler | Overweight |
| 2022-12-19 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | Fortgesetzt | Goldman | Buy |
| 2020-11-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-11-06 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-05 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-05-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-01-30 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-01-09 | Hochstufung | UBS | Neutral → Buy |
| 2019-11-07 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-25 | Eingeleitet | Stifel | Hold |
| 2019-06-10 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Neutral |
| 2018-11-19 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-09-04 | Eingeleitet | Citigroup | Buy |
| 2018-08-06 | Herabstufung | Goldman | Buy → Neutral |
| 2018-06-28 | Eingeleitet | Raymond James | Mkt Perform |
Alle ansehen
Madrigal Pharmaceuticals Inc Aktie (MDGL) Neueste Nachrichten
Madrigal Pharmaceuticals, Inc. (MDGL): Among Nicholas J. Pritzker’s Stock Picks with Huge Upside Potential - Yahoo
Billionaire Nicholas J. Pritzker’s 8 Stocks with Huge Upside Potential - Insider Monkey
Madrigal Pharmaceuticals (MDGL): Among Billionaire John Paulson’s Stocks with Huge Upside Potential - Insider Monkey
Madrigal Pharmaceuticals: An Encouraging Start For Rezdiffra (NASDAQ:MDGL) - Seeking Alpha
Billionaire John Paulson’s 10 Stocks with Huge Upside Potential - Insider Monkey
Earnings Beat: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - simplywall.st
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2025 Earnings Call Transcript - Insider Monkey
Decoding Madrigal Pharmaceuticals Inc (MDGL): A Strategic SWOT I - GuruFocus
(MDGL) Trading Signals - news.stocktradersdaily.com
Madrigal Pharmaceuticals (MDGL): UBS Maintains Buy Rating, Raise - GuruFocus
Madrigal Pharmaceuticals (MDGL): UBS Maintains Buy Rating, Raises Price Target | MDGL Stock News - GuruFocus
Madrigal Pharmaceuticals (MDGL) Target Price Raised by Canaccord - GuruFocus
Madrigal Pharmaceuticals (MDGL) Receives a Price Target Boost fr - GuruFocus
Madrigal Pharmaceuticals (MDGL) Receives a Price Target Boost from B. Riley Securities | MDGL Stock News - GuruFocus
Madrigal Pharmaceuticals (MDGL) Sees Price Target Boost on Stron - GuruFocus
UBS Increases Price Target for Madrigal Pharmaceuticals (MDGL) | - GuruFocus
UBS Increases Price Target for Madrigal Pharmaceuticals (MDGL) | MDGL Stock News - GuruFocus
Madrigal Pharmaceuticals (MDGL) Sees Price Target Boost on Strong Sales | MDGL Stock News - GuruFocus
Madrigal Pharmaceuticals to Present Breakthrough Resmetirom Data at EASL Congress 2025 - MSN
UBS Adjusts Madrigal Pharmaceuticals Price Target to $458 From $441, Maintains Buy Rating - marketscreener.com
Madrigal Pharmaceuticals (MDGL) Receives Increased Price Target from Analyst | MDGL Stock News - GuruFocus
Madrigal Pharmaceuticals Inc (MDGL) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo Finance
Madrigal Pharmaceuticals Reports Strong Q1 2025 Results - TipRanks
Madrigal: Q1 Earnings Snapshot - Huron Daily Tribune
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up - Zacks Investment Research
Madrigal Pharmaceuticals Q1 Loss Narrows - marketscreener.com
Earnings call transcript: Madrigal Pharmaceuticals beats Q1 2025 EPS forecasts - Investing.com
Madrigal Pharmaceuticals Inc Q1 2025 Earnings: Revenue Surpasses - GuruFocus
Madrigal Pharmaceuticals Inc Q1 2025 Earnings: Revenue Surpasses Estimates at $137.3 Million, Operating Loss Reported - GuruFocus
Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates - The Manila Times
Madrigal Pharmaceuticals (MDGL) Reports Strong Q1 Revenue Exceed - GuruFocus
Madrigal’s MASH drug sales again top Wall Street projections - Yahoo Finance
Madrigal stock holds neutral as 1Q revenue beats estimates By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals (MDGL) to Present Key Findings at EASL - GuruFocus
Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress - The Manila Times
Madrigal to Present Late-Breaking Resmetirom Data in - GlobeNewswire
Insiders At Madrigal Pharmaceuticals Sold US$4.4m In Stock, Alluding To Potential Weakness - simplywall.st
Citizens JMP reiterates Madrigal stock with $443 target By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals to Announce Q1 2025 Results with Live Webcast - MSN
Leadership Changes at Madrigal Pharmaceuticals Mark New Phase of Growth - MSN
Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025 | MDGL Stock News - GuruFocus
Madrigal Pharmaceuticals to Release Q1 2025 Financial Results on May 1, 2025 - Nasdaq
Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025 - GlobeNewswire
Madrigal Pharmaceuticals announces executive transition By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals announces executive transition - Investing.com Australia
Madrigal Pharmaceuticals Announces Leadership Transition - TipRanks
(MDGL) Technical Data - news.stocktradersdaily.com
Madrigal founder Rebecca Taub to step back; firm hires successor from Novartis - The Business Journals
Madrigal Pharmaceuticals Appoint Rebecca Taub, M.D. as Senior Scientific and Medical Advisor; David Soergel, M.D., Appointed CMO - citybiz
Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D., Appointed Chief Medical Officer - The Manila Times
Madrigal Pharmaceuticals Announces Company Founder Rebecca - GlobeNewswire
Finanzdaten der Madrigal Pharmaceuticals Inc-Aktie (MDGL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.84%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):